Characteristics of immediate anti-CD20 adverse drug reactions

被引：0
|
作者：
Yotinnoratham, N. [1 ]
Laisuan, W. [1 ]
机构：
[1] Mahidol Univ, Ramathibodi Hosp, Bangkok, Thailand
来源：
ALLERGY | 2021年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
476
引用
收藏
页码：269 / 269
页数：1
相关论文
共 50 条
  • [41] Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome
    Bonanni, Alice
    Calatroni, Marta
    D'Alessandro, Matteo
    Signa, Sara
    Bertelli, Enrica
    Cioni, Michela
    Di Marco, Eddi
    Biassoni, Roberto
    Caridi, Gianluca
    Ingrasciotta, Giulia
    Bertelli, Roberta
    Di Donato, Armando
    Bruschi, Maurizio
    Canepa, Alberto
    Piaggio, Giorgio
    Ravani, Pietro
    Ghiggeri, Gian Marco
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (06) : 1238 - 1249
  • [42] Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity
    Rossi, Edmund A.
    Chang, Chien-Hsing
    Cardillo, Thomas M.
    Stein, Rhona
    Pilas, Diana
    Nordstrom, Diane L.
    Kopinski, John
    Goldenberg, David M.
    [J]. BLOOD, 2008, 112 (11) : 564 - 565
  • [43] Multiple signaling pathways of hexavalent anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized monoclonal antibodies correlate with improved anti-lymphoma properties
    Gupta, Pankaj
    Goldenberg, David
    Chang, Chien-Hsing
    [J]. CANCER RESEARCH, 2009, 69
  • [44] Obinutuzumab: a new class of anti-CD20 monoclonal antibody
    Gagez, Anne-Laure
    Cartron, Guillaume
    [J]. CURRENT OPINION IN ONCOLOGY, 2014, 26 (05) : 484 - 491
  • [45] Anti-CD20 treatments and the lymphocyte membrane: Pathology for therapy
    Borisch, B
    Semac, I
    Soltermann, A
    Palomba, C
    Hoessli, DC
    [J]. VERHANDLUNGEN DER DEUTSCHEN GESELLSCHAFT FUR PATHOLOGIE 85. TAGUNG: PATHOLOGIE FUR DAS 21. JAHRHUNDERT, 2001, 85 : 161 - 166
  • [46] CHARACTERIZATION OF A PATIENTS' ANTIBODIES TO THE ANTI-CD20 THERAPEUTIC RITUXIMAB
    Mahadik, Younis
    Young, Stephen
    Morgan, Matthew
    Gordon, Caroline
    Harper, Lorraine
    [J]. RHEUMATOLOGY, 2012, 51 : 142 - 143
  • [47] Should anti-CD20 be used as an immune reconstitution therapy?
    Smets, Ide
    Wokke, Beatrijs
    Smolders, Joost
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (02) : 308 - 310
  • [48] Anti-CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis
    Korhonen, Riku
    Moilanen, Eeva
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 106 (01) : 13 - 21
  • [49] Anti-CD20 monoclonal antibodies: historical and future perspectives
    Lim, Sean H.
    Beers, Stephen A.
    French, Ruth R.
    Johnson, Peter W. M.
    Glennie, Martin J.
    Cragg, Mark S.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (01): : 135 - 143
  • [50] What signals are generated by anti-CD20 antibody therapy?
    Bonavida B.
    [J]. Current Hematologic Malignancy Reports, 2006, 1 (4) : 205 - 213
12345